EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic Burden of Post-COVID Syndrome in Germany Between 2021 and 2025: A Statutory Health Insurance Claims Data Analysis

Daniel Gensorowsky iD, Emma Fröling iD, Kylie Braegelmann iD, Jana Diekmannshemke iD, Agnes Kisser iD, Philipp Reuken iD, Jessica Noll iD, Julia Blaurock iD, Eveline Otte Im Kampe iD

Journal of Health Economics and Outcomes Research · 21.10.2026 · 13 (2)

DOI: 10.36469/001c.170196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 21.10.2026. Verfasst von Daniel Gensorowsky und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vandage GmbH, Bielefeld, Germany. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence on the economic burden of post-COVID syndrome in Germany remains limited. This study quantifies post-COVID-associated healthcare resource utilization (HCRU), sick leave, and costs.

Objectives

To compare HCRU, sick leave, and costs borne by the statutory health insurance (SHI) among incident pediatric and adult post-COVID patients with matched post-COVID-free controls.

Methods

This retrospective cohort study analyzed an anonymized German SHI claims database provided by GWQ ServicePlus AG. The observation period spanned October 2021 to June 2025 and included all individuals with incident COVID-19 diagnosis until September 2024. Incident post-COVID was defined as the first ICD-10-GM code (U07.4!; U09.9!) recorded ≥90 days after first COVID-19 diagnosis. Post-COVID cases were exactly matched 1:2 to post-COVID–free COVID-19 controls by calendar quarter of incident COVID-19 diagnosis, acute severity, cohort entry quarter, 5-year birth interval, sex, and Elixhauser Comorbidity Index. We estimated mean differences in HCRU, sick leave, and direct SHI-borne costs per case. Rate ratios of HCRU, sick leave, and costs per person-year were estimated using Poisson (HCRU/sick leave) and linear (costs) regression. Analyses covered 365-day, 730-day, and any follow-up period.

Results

We matched 25 485 identified post-COVID cases with 49 671 controls. Matched cases and controls were comparable in age, sex, and comorbidities. Overall, during 365 days of follow-up, post-COVID patients showed higher HCRU and sick leave rates across all sectors, especially sick leave days. Mean differences per case were greatest for sick leave days (365 days: +27 days) and outpatient physician contacts (365 days: 6.9 contacts). HCRU and sick leave rates remained significantly increased over extended follow-up periods. Total SHI-borne costs per person-year were higher among post-COVID patients across all follow-up periods (all P < .001). Sector-specific costs per person-year were increased primarily in the outpatient sector and for sickness benefits (all P < .001). Mean total cost differences per case were +€1806 per case (365 days) and mean excess sickness benefits per case were +€1077.

Conclusions

Documented post-COVID was associated with a substantial and sustained economic burden on the German healthcare system and society. Targeted strategies are needed to mitigate potential long-term impacts on HCRU and labor productivity.

Schlagwörter

Stichwörter der Autor:innen

COVID-19cost of illnesseconomic burdenhealthcare resource utilizationlong COVIDpost-COVIDsick leave

Autor:innen und Institutionen

  • Vandage GmbH, Bielefeld, Germany.
  • Pfizer Pharma GmbH, Berlin, Germany.
  • Universitätsklinikum Jena, Jena, Germany.

ORCID-Profile: Daniel Gensorowsky, Emma Fröling, Kylie Braegelmann, Jana Diekmannshemke, Agnes Kisser, Philipp Reuken, Jessica Noll, Julia Blaurock, Eveline Otte Im Kampe

Zitieren

APA

Gensorowsky, D., Fröling, E., Braegelmann, K., Diekmannshemke, J., Kisser, A., Reuken, P., Noll, J., Blaurock, J., & Otte Im Kampe, E. (2026). Economic Burden of Post-COVID Syndrome in Germany Between 2021 and 2025: A Statutory Health Insurance Claims Data Analysis. Journal of Health Economics and Outcomes Research, 13(2). https://doi.org/10.36469/001c.170196

Vancouver

Gensorowsky D, Fröling E, Braegelmann K, Diekmannshemke J, Kisser A, Reuken P, et al. Economic Burden of Post-COVID Syndrome in Germany Between 2021 and 2025: A Statutory Health Insurance Claims Data Analysis. Journal of Health Economics and Outcomes Research. 2026;13(2). doi:10.36469/001c.170196

BibTeX
@article{Gensorowsky2026,
  author = {Gensorowsky, Daniel and Fröling, Emma and Braegelmann, Kylie and Diekmannshemke, Jana and Kisser, Agnes and Reuken, Philipp and Noll, Jessica and Blaurock, Julia and Otte Im Kampe, Eveline},
  title = {Economic Burden of Post-COVID Syndrome in Germany Between 2021 and 2025: A Statutory Health Insurance Claims Data Analysis},
  journal = {Journal of Health Economics and Outcomes Research},
  year = {2026},
  volume = {13},
  number = {2},
  doi = {10.36469/001c.170196}
}
Kostenlos starten →